Zhou Dongsheng, Liang Jianzhong, Xu L I, He Fengying, Zhou Zhongguo, Zhang Yaojun, Chen Minshan
Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China; Department of Surgery, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P.R. China.
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
Oncol Lett. 2016 May;11(5):2987-2994. doi: 10.3892/ol.2016.4359. Epub 2016 Mar 21.
The derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor for cancer patients, but the prognostic significance of the dNLR in hepatocellular carcinoma (HCC) has not been investigated. The present study aimed to validate the prognostic power of the NLR and dNLR in HCC patients undergoing transarterial chemoembolization (TACE). The data of 279 consecutive patients who underwent TACE for unresectable HBV-associated HCC between September 2009 and November 2011 at the Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center (Guangzhou, China) were retrieved from a prospective database. The cut-off values for the NLR and dNLR were determined by receiver operating characteristic (ROC) analysis. The association between the NLR and dNLR and the clinicopathological characteristics and overall survival (OS) rates and times of patients was analyzed. The area under the curve (AUC) was calculated to evaluate the discriminatory ability of the NLR and dNLR. The median follow-up period was 446 days, the 1, 2 and 3-year OS rates were 38.8, 18.5 and 11.1% respectively, and the median OS time was 264 days. The cut-off values were determined as 2.6 and 1.8 for the NLR and dNLR, respectively. The NLR and dNLR were each associated with patient age, presence of vascular invasion, tumor size, AST level and ALP level. Multivariate analysis showed that the NLR, dNLR, ALT level and AFP level were independent prognostic factors for OS. An elevated NLR or dNLR was associated with a poor prognosis (P=0.001 and P=0.002, respectively). The prognostic power of NLR [AUC=0.539; 95% confidence interval (CI), 0.423-0.656] and dNLR (AUC=0.522; 95% CI, 0.406-0.638) was similar. Elevated dNLR predicted poor prognosis for patients with HBV-associated HCC undergoing TACE, with similar prognostic power to NLR. The dNLR may be used as an alternative to the NLR, as it is easily available and inexpensive.
衍生中性粒细胞与淋巴细胞比值(dNLR)已被提出作为癌症患者一种易于测定的预后因素,但dNLR在肝细胞癌(HCC)中的预后意义尚未得到研究。本研究旨在验证NLR和dNLR对接受经动脉化疗栓塞术(TACE)的HCC患者的预后预测能力。我们从中山大学肿瘤防治中心(中国广州)肝胆外科的前瞻性数据库中检索了2009年9月至2011年11月期间连续279例因不可切除的HBV相关HCC接受TACE治疗患者的数据。通过受试者工作特征(ROC)分析确定NLR和dNLR的截断值。分析NLR和dNLR与患者临床病理特征、总生存(OS)率及生存时间之间的关联。计算曲线下面积(AUC)以评估NLR和dNLR的鉴别能力。中位随访期为446天,1、2和3年OS率分别为38.8%、18.5%和11.1%,中位OS时间为264天。NLR和dNLR的截断值分别确定为2.6和1.8。NLR和dNLR均与患者年龄、血管侵犯情况、肿瘤大小、AST水平和ALP水平相关。多因素分析显示,NLR、dNLR、ALT水平和AFP水平是OS的独立预后因素。NLR或dNLR升高与预后不良相关(分别为P = 0.001和P = 0.002)。NLR [AUC = 0.539;95%置信区间(CI),0.423 - 至0.656]和dNLR(AUC = 0.522;95% CI,0.406 - 0.638)具有相似的预后预测能力。dNLR升高预示接受TACE治疗的HBV相关HCC患者预后不良,其预后预测能力与NLR相似。由于dNLR易于获取且成本低廉,它可作为NLR的替代指标。